BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sasanlimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sasanlimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05665361-1971@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Sasanlimab: Phase 1/2 readout est. (NCT05665361)
DESCRIPTION:Sasanlimab\, phase 1/2.\nStudy: Palbociclib and Sasanlimab for 
 the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papil
 lary Renal Cell Carcinoma (pRCC)\nEstimated primary completion: 1 June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sasanlimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05665361
URL:https://assetmemo.bio/drug/sasanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123090-1971@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Sasanlimab: Phase 2 readout est. (NCT07123090)
DESCRIPTION:Sasanlimab\, phase 2.\nStudy: A Study of Sasanlimab\, Palbocicl
 ib and Axitinib in Metastatic Renal Cell Carcinoma\nEstimated primary comp
 letion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sasanlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07123090
URL:https://assetmemo.bio/drug/sasanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206225-1971@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20300129
DTEND;VALUE=DATE:20300130
SUMMARY:Sasanlimab: Phase 1 readout est. (NCT07206225)
DESCRIPTION:Sasanlimab\, phase 1.\nStudy: A Study to Learn About the Study 
 Medicine PF-08052667 in People With Bladder Cancer\nEstimated primary comp
 letion: 29 January 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sasanlimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07206225
URL:https://assetmemo.bio/drug/sasanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
